GlassScriptPhysician profile
Stephen C Karem
NPI 1295719664
$2,516.78
in general payments reported to CMS, 2019-2025
29 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $1,033 · 2021: $509 · 2022: $62.39 · 2023: $21.05 · 2024: $59.36 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $279.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $303.69 | 2019-2021 | |
| Allergan, INC. | $277.39 | 2019-2020 | |
| Amgen INC. | $233.02 | 2019-2025 | Repatha, Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $226.51 | 2020-2021 | |
| Boston Scientific Corporation | $167.53 | 2021 | |
| Axsome Therapeutics, INC. | $148.46 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $146.33 | 2019-2021 | |
| Novo Nordisk INC | $141.09 | 2019-2021 | |
| Amarin Pharma, INC. | $104.19 | 2019-2020 | |
| Abbvie INC. | $92.48 | 2020-2022 | |
| Lilly USA, LLC | $84.34 | 2021-2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $82.09 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $64.20 | 2019 | |
| Eisai INC. | $59.11 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $55.85 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $47.70 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $31.09 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.40 | 2019-2020 | |
| Dermira, INC. | $27.45 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.99 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $26.21 | 2019-2021 | |
| Horizon Therapeutics Plc | $26.10 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.84 | 2021 | |
| Esperion Therapeutics, INC. | $18.81 | 2024 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $17.59 | 2022 | |
| Mylan Specialty L.P. | $15.93 | 2019 | |
| Alnylam Pharmaceuticals INC. | $15.31 | 2021 | |
| Ironwood Pharmaceuticals, INC | $14.76 | 2019 | |
| Tris Pharma INC | $14.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Karem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.